Victor C. Kok

1.5k total citations · 1 hit paper
54 papers, 1.1k citations indexed

About

Victor C. Kok is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Victor C. Kok has authored 54 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in Victor C. Kok's work include Air Quality and Health Impacts (4 papers), Cancer Genomics and Diagnostics (3 papers) and Neuroendocrine Tumor Research Advances (3 papers). Victor C. Kok is often cited by papers focused on Air Quality and Health Impacts (4 papers), Cancer Genomics and Diagnostics (3 papers) and Neuroendocrine Tumor Research Advances (3 papers). Victor C. Kok collaborates with scholars based in Taiwan, United States and Japan. Victor C. Kok's co-authors include Cheng‐Chia Yu, Jorng‐Tzong Horng, Horng-Jyh Tsai, Yu‐Ching Chen, Hanwei Zhang, Tzu‐Hao Chang, Cheng-Wei Chang, Jang‐Jih Lu, Ka‐Lok Ng and Chin‐Teng Lin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Victor C. Kok

53 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

<p>Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development</p>

2020 313 citations Victor C. Kok et al. profile →

Peers

Countries citing papers authored by Victor C. Kok

Since Specialization

Citations

This map shows the geographic impact of Victor C. Kok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor C. Kok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor C. Kok more than expected).

Fields of papers citing papers by Victor C. Kok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor C. Kok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor C. Kok. The network helps show where Victor C. Kok may publish in the future.

Co-authorship network of co-authors of Victor C. Kok

This figure shows the co-authorship network connecting the top 25 collaborators of Victor C. Kok. A scholar is included among the top collaborators of Victor C. Kok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor C. Kok. Victor C. Kok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Select gene mutations associated with survival outcomes in ER‐positive ERBB2‐negative early‐stage invasive breast cancer: A single‐institutional tissue bank study 2024 ·Cancer Medicine ·Victor C. Kok, (unknown), Yi‐Chiung Hsu, Yuan‐Ching Chang, Po‐Sheng Yang	2
2	Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers 2022 ·Breast Cancer Research and Treatment ·Ambily Sivadas, Victor C. Kok, Ka‐Lok Ng	15
3	The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics 2021 ·Journal of Experimental & Clinical Cancer Research ·Elizabeth Cash, Sandra E. Sephton, (unknown), (unknown), (unknown), (unknown), Victor C. Kok	35
4	Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report 2021 ·Frontiers in Oncology ·Victor C. Kok, (unknown), (unknown), (unknown), (unknown), (unknown), Pei‐Yu Lee, Kebin Wang	2
5	Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study 2019 ·Cancers ·Victor C. Kok, Yu‐Ching Chen, Yang‐Yuan Chen, Yu‐Chieh Su, (unknown), (unknown), Go J. Yoshida	31
6	Gout as a risk factor for osteoporosis: epidemiologic evidence from a population-based longitudinal study involving 108,060 individuals 2018 ·Osteoporosis International ·Victor C. Kok, Jorng‐Tzong Horng, (unknown), (unknown), (unknown), (unknown)	26
7	ESOPHAGOPERICARDIAL FISTULA AND PURULENT PERICARDITIS CAUSING CARDIAC TAMPONADE DURING CONCURRENT CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER: A CASE REPORT 2017 ·(unknown), (unknown), Victor C. Kok	2
8	Bidirectional risk between venous thromboembolism and cancer in East Asian patients: synthesis of evidence from recent population-based epidemiological studies 2017 ·Cancer Management and Research ·Victor C. Kok	8
9	Diagnostic value of serum procalcitonin, lactate, and high-sensitivity C-reactive protein for predicting bacteremia in adult patients in the emergency department 2017 ·PeerJ ·(unknown), Jang‐Jih Lu, Yu‐Ching Chen, Victor C. Kok, Jorng‐Tzong Horng	33
10	Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment 2016 ·BMC Urology ·Victor C. Kok, (unknown)	7
11	Primary Vaginal Melanoma With Rhabdoid Features: A Case Report and Literature Review 2016 ·International Journal of Gynecological Pathology ·(unknown), Ho Lin, (unknown), Victor C. Kok	5
12	Clinical analysis of contributors to the delayed gallbladder opacification following the use of water-soluble contrast medium 2016 ·Therapeutics and Clinical Risk Management ·Victor C. Kok, (unknown), Ming‐Yung Lee, (unknown), (unknown), Che-Wei Chang, Yeu‐Sheng Tyan, (unknown)	3
13	Risk and clinical predictors of osteoporotic fracture in East Asian patients with chronic obstructive pulmonary disease: a population-based cohort study 2016 ·PeerJ ·(unknown), Victor C. Kok, (unknown), (unknown), Yu‐Ching Chen, Jorng‐Tzong Horng	10
14	Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator 2015 ·Therapeutics and Clinical Risk Management ·Victor C. Kok, Yu‐Ching Chen, (unknown), Jorng‐Tzong Horng, (unknown)	30
15	The Risks for Ovarian, Endometrial, Breast, Colorectal, and Other Cancers in Women With Newly Diagnosed Endometriosis or Adenomyosis 2015 ·International Journal of Gynecological Cancer ·Victor C. Kok, Horng-Jyh Tsai, (unknown), (unknown)	102
16	Compassionate extubation for a peaceful death in the setting of a community hospital: a case-series study 2015 ·Clinical Interventions in Aging ·Victor C. Kok	14
17	Population-based cohort study on the risk of malignancy in East Asian children with Juvenile idiopathic arthritis 2014 ·BMC Cancer ·Victor C. Kok, Jorng‐Tzong Horng, Jing‐Long Huang, Kuo-Wei Yeh, (unknown), Cheng-Wei Chang, (unknown)	30
18	Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan 2013 ·Journal of Cancer Research and Therapeutics ·Tsu-Yi Chao, Po‐Hui Chiang, Hwei-Chung Wang, Yuen‐Liang Lai, (unknown), (unknown), Victor C. Kok, Yen-Chuan Ou, (unknown), Tzu‐Chuan Huang	10
19	Diabetic Patients with Severe Sepsis Admitted to Intensive Care Unit Do Not Fare Worse than Non-Diabetic Patients: A Nationwide Population-Based Cohort Study 2012 ·PLoS ONE ·Cheng-Wei Chang, Victor C. Kok, Joseph T. Tseng, Jorng‐Tzong Horng, Chun-Eng Liu	32
20	Concomitant renal cell carcinoma and metastatic epithelioid angiosarcoma with microangiopathy. 1995 ·PubMed ·Victor C. Kok, (unknown), (unknown), (unknown), (unknown), (unknown), Aihua Huang	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact